Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week. Topics include all stories related to hepatitis C as well as personal stories and events.
Week Ending 04/19/2015
‘A study of over 3,000 eligible subjects in the Electronically Retrieved Cohort of Hepatitis C Viral (HCV) Infected Veterans (ERCHIVES) identified that statin use may be beneficial to sustained virologic response (SVR) rates, limiting fibrosis progression, and preventing the incidence of hepatocellular carcinoma (HCC).’
‘Cepheid said today that it has received a CE IVD mark for Xpert HCV Viral Load, a test that provides quantitative, on-demand confirmation of infection and monitoring of hepatitis C virus. The test is intended for use as an aid in the management of HCV-infected patients undergoing antiviral therapy. It can be used to measure HCV RNA levels at baseline and during treatment, and to help predict sustained and nonsustained virological responses to HCV therapy. In addition, it can be used to confirm HCV serologic test results.’
‘Merck announced that the FDA has granted Breakthrough Therapy designation to grazoprevir/elbasvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis.’
‘Staggering price tags for new drugs that treat a small number of patients could threaten the affordability of all prescription medicine, a major patient advocacy group said recently. “Prices are way too high, much higher than they need to be,” said Peter Bach, director of Memorial Sloan Kettering’s Center of Health Policy and Outcomes.’
‘Modest consumption of caffeinated drinks is associated with less advanced liver scarring in patients with hepatitis C, results of a study published in Clinical Gastroenterology and Hepatology suggest. To investigate the effect of modest daily caffeine consumption and liver scarring, Hashem El-Seng, MD, MPH, of Baylor College of Medicine in Houston, Texas, and colleagues conducted a cross-sectional study of 910 participants, aged 18 to 70 years.’